Kymera Therapeutics Inc (KYMR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $10.89B
Last updated: Nov 17, 2026 at 11:06 AM ET
Kymera Therapeutics Inc (KYMR) Stock Forecast
Analysts expect Kymera Therapeutics (KYMR) to earn -$3.93 per share in the fiscal year ending Dec 31, 2026, on revenue of $99.39M. Of 24 analysts, 22 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 8 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 24 ratings average 1.88, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 92% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 5 | 20.8% |
| Buy | 17 | 70.8% |
| Hold | 2 | 8.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 24
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 57.7%.
- Fiscal year ending Dec 31, 2026
- -$3.93
- EPS consensus, revenue $99.39M
- Fiscal year ending Dec 31, 2027
- -$5.12
- EPS consensus, revenue $42.03M
- Next report
- Feb 24, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$3.93 | -$4.21 to -$3.13 | 22 | $99.39M | $98.00M to $101.40M | 21 |
| Dec 31, 2027 | -$5.12 | -$6.70 to -$3.36 | 22 | $42.03M | N/A | 23 |
Quarterly Estimates
The EPS consensus falls from -$1.33 for the quarter ending Dec 31, 2026 to -$1.35 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.33 | -$1.51 to -$0.82 | 27 | $545986 | N/A | 24 |
| Mar 31, 2027 | -$1.35 | -$1.52 to -$1.08 | 7 | $7.00M | N/A | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 8 upward and 16 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 8 |
| Fiscal year ending Dec 31, 2027 | 5 | 7 |
| Quarter ending Mar 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$3.51.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.93 | -$3.85 | -$3.84 | -$3.78 | -$3.51 | N/A |
| Fiscal year ending Dec 31, 2027 | -$5.12 | -$5.10 | -$5.10 | -$4.94 | -$4.36 | N/A |
| Quarter ending Mar 31, 2027 | -$1.35 | -$1.36 | -$1.36 | -$1.26 | -$1.06 | N/A |
Frequently Asked Questions About KYMR
What is the KYMR stock forecast?
Consensus analyst estimates put Kymera Therapeutics's EPS at -$3.93 for the fiscal year ending Dec 31, 2026, on revenue of $99.39M. The consensus rating from 24 analysts is Buy.
How do analysts rate KYMR stock?
Of 24 analysts covering Kymera Therapeutics, 5 rate it Strong Buy, 17 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from KYMR next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.93, with estimates from -$4.21 to -$3.13 from 22 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$5.12, with estimates from -$6.70 to -$3.36 from 22 analysts.
What revenue do analysts expect from Kymera Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $99.39M, with estimates from $98.00M to $101.40M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $42.03M.
How many analysts cover KYMR?
24 analysts rate Kymera Therapeutics stock, and 22 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
KYMR pages: Overview, Earnings, Forecast, Financials, Competitors